Ardena completes divestment of its Sodertalje drug substance site in Sweden to Nanologica
Ghent, Belgium, 29th January 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, today announced that it has completed the divestment of its drug substance (API) site in Sodertalje, Sweden, to Nanologica AB. The business will operate as a wholly owned subsidiary within the Nanologica Group and will […]